title: Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX.
abstract: There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 patients with advanced pancreatic cancer treated with FOLFIRINOX therapy. The association of ETS with progression-free survival (PFS) and overall survival (OS) was evaluated but also we addressed to the correlation between outcomes and DpR. ETS was defined as a reduction ≥ 20% of target lesions' diameters measured at 6 to 8 weeks from treatment start. DpR was percentage of maximal tumor shrinkage observed at the nadir diameter compared with baseline. Among 47 evaluable patients for the ETS, 12 (25.5%) patients experienced ETS. The ETS was significantly associated with better PFS (9.0 vs. 4.2 months) as well as OS (24.0 vs. 9.1 months); moreover, the association had a statistically significance for PFS but a strong trend for OS in multivariate analysis. The DpR was statistically significantly but weakly associated with OS. In conclusion, this is the first report that the early response to chemotherapy may predict favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX therapy.
authors.affiliation: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kaga
authors.affiliation: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Sunakawa
authors.affiliation: Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
authors.forename: Yutaro
authors.initials: Y
authors.lastname: Kubota
authors.affiliation: Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
authors.forename: Teppei
authors.initials: T
authors.lastname: Tagawa
authors.affiliation: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
authors.forename: Taikan
authors.initials: T
authors.lastname: Yamamoto
authors.affiliation: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Ikusue
authors.affiliation: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Uto
authors.affiliation: Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
authors.forename: Kouichirou
authors.initials: K
authors.lastname: Miyashita
authors.affiliation: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Toshima
authors.affiliation: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan.
authors.forename: Kouji
authors.initials: K
authors.lastname: Kobayashi
authors.affiliation: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hisamatsu
authors.affiliation: Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
authors.forename: Wataru
authors.initials: W
authors.lastname: Ichikawa
authors.affiliation: Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Sekikawa
authors.affiliation: Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Shimada
authors.affiliation: Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
authors.forename: Yasutsuna
authors.initials: Y
authors.lastname: Sasaki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016896:Treatment Outcome
keywords: FOLFIRINOX; early tumor shrinkage; pancreatic cancer